Tech Company Financing Transactions
SanegeneBio Funding Round
SanegeneBio closed a $110 million Series B funding round on 12/12/2025. Backers included Eli Lilly and Company, Invus and Lake Bleu Capital.
Transaction Overview
Company Name
Announced On
12/12/2025
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 Tradecenter Dr
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Undisclosed
Website
Email Address
Overview
SanegeneBio is a global biotech with a singular vision: Best-in-class RNAi medicines. We are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology. Our proprietary technology platform, LEAD� (Ligand and Enhancer Assisted Delivery), enables tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells--achieved through safe, infrequent subcutaneous dosing. SanegeneBio is committed to advancing transformative RNAi therapies that address global unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Weimin Wang
Browse more venture capital transactions:
Prev: 12/12/2025: Beyond Now venture capital transaction
Next: 12/12/2025: Valinor venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs